RETRACTED ARTICLE: The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

1. Quality of clinical evidence and political justifications of ivermectin mass distribution of COVID-19 kits in eight Latin American countries.BMJ global health · 2023
   Pooled it
2. Identification of Natural Compounds as Potential COVID-19 Main Protease (Mpro) Inhibitors: A Comprehensive Study andCurrent pharmaceutical design · 2025
   Review
3. Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects.Cureus · 2022
   Article
4. Ivermectin in COVID-19: The Case for a Moratorium on Prescriptions.Therapeutic innovation & regulatory science · 2022
   Article
5. Antiviral Activity of Repurposing Ivermectin against a Panel of 30 Clinical SARS-CoV-2 Strains Belonging to 14 Variants.Pharmaceuticals (Basel, Switzerland) · 2022
   Article
6. Advances in the Prophylaxis of Respiratory Infections by the Nasal and the Oromucosal Route: Relevance to the Fight with the SARS-CoV-2 Pandemic.Pharmaceutics · 2022
   Review
7. CD147-spike protein interaction in COVID-19: Get the ball rolling with a novel receptor and therapeutic target.The Science of the total environment · 2022
   Review
8. Repurposing the drug, ivermectin, in COVID-19: toxicological points of view.European journal of medical research · 2022
   Review
9. Notice to readers regarding the retraction note included in this issue.The Journal of antibiotics · 2022
   Article
10. Harnessing autophagy to fight SARS-CoV-2: An update in view of recent drug development efforts.Journal of cellular biochemistry · 2022
    Review
11. Treatments for COVID-19: Lessons from 2020 and new therapeutic options.Current opinion in pharmacology · 2022
    Review
12. Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching.Cureus · 2022
    Article
13. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2021
    Review
14. Molecular Docking and Dynamics Simulation Revealed Ivermectin as Potential Drug againstMedicina (Kaunas, Lithuania) · 2021
    Article
15. Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19.New microbes and new infections · 2021
    Review
16. Repurposing of Drugs for SARS-CoV-2 Using Inverse Docking Fingerprints.Frontiers in chemistry · 2021
    Article
17. Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics.Frontiers in immunology · 2021
    Review

Corrections and comments

• Retraction · 2021-09-27Concerns/Issues about Article · Error in Methods · Objections by Author(s) · Retract and Replace · Unreliable Results and/or Conclusions · · see also: https://www.nature.com/articles/s41429-022-00501-1 and https://www.nature.com/articles/s41429-021-00491-6, and https://pubpeer.com/publications/EDF9109EE29DF2340379B562365FE5
• Commented on by
  Notice to readers regarding the retraction note included in this issue.2022
• RetractedandRepublishedIn
  The mechanisms of action of ivermectin against SARS-CoV-2-an extensive review.2022

Authors and funding

2 authors at 2 institutions in 3 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.